Merck & Co., Inc.

NYSE MRK

Merck & Co., Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 20.75

Merck & Co., Inc. Price to Earnings Ratio (P/E) is 20.75 on January 14, 2025, a -97.47% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Merck & Co., Inc. 52-week high Price to Earnings Ratio (P/E) is 914.83 on March 28, 2024, which is 4,308.70% above the current Price to Earnings Ratio (P/E).
  • Merck & Co., Inc. 52-week low Price to Earnings Ratio (P/E) is 20.06 on November 15, 2024, which is -3.35% below the current Price to Earnings Ratio (P/E).
  • Merck & Co., Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 225.79.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NYSE: MRK

Merck & Co., Inc.

CEO Mr. Robert M. Davis J.D.
IPO Date Jan. 13, 1978
Location United States
Headquarters 2000 Galloping Hill Road
Employees 70,000
Sector Health Care
Industries
Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Similar companies

BMY

Bristol-Myers Squibb Company

USD 55.74

0.69%

PFE

Pfizer Inc.

USD 26.41

-1.46%

LLY

Eli Lilly and Company

USD 744.91

-6.59%

JNJ

Johnson & Johnson

USD 144.75

0.19%

ABBV

AbbVie Inc.

USD 175.55

-0.67%

GILD

Gilead Sciences, Inc.

USD 91.00

1.18%

AMGN

Amgen Inc.

USD 267.10

-1.14%

StockViz Staff

January 15, 2025

Any question? Send us an email